An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure

(2011) Nizar M. Tannir et al.   EUROPEAN JOURNAL OF CANCER

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

(2011) Eng-Huat Tan et al.   Journal of Thoracic Oncology

Phase I trial of SU14813 in patients with advanced solid malignancies

(2010) W. Fiedler et al.   ANNALS OF ONCOLOGY

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

(2010) D. J. Jonker et al.   ANNALS OF ONCOLOGY

Angiogenesis Inhibitors: Current Strategies and Future Prospects

(2010) K. M. Cook et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

(2010) Yasuhito Fujisaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

(2009) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients

(2009) Toru Mukohara et al.   CANCER SCIENCE

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies

(2009) Chiung-Ing Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

(2008) Nancy Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY